Type 2 Diabetes Mellitus

Metabolic·MeSH: Diabetes Mellitus, Type 2

Prevalence

10700.0 / 100K

Incidence

600.0 / 100K/yr

29 drugs in development·20 companies·20 clinical trials

Drug Pipeline by Phase

Approved(6)

Drug	Company
exenatide synthetic	Amneal Pharmaceuticals, Inc. (AMRX)
inpefa	LEXICON PHARMACEUTICALS, INC. (LXRX)
linagliptin	Mylan II B.V. (MYL)
metformin	Inventiva S.A. (IVA)
ozempic	Novo Nordisk A/S (NVO)
saxagliptin	Mylan II B.V. (MYL)

Phase 3(7)

Drug	Company
AZD6793	ASTRAZENECA PLC (AZN)
BYDUREON	ENANTA PHARMACEUTICALS INC (ENTA)
Dulaglutide	ELI LILLY & Co (LLY)
idegasp	Sanofi (SNY)
insulin glargine/lixisenatide	Sanofi (SNY)
ormd-0801	ORAMED PHARMACEUTICALS INC. (ORMP)
sglt2 inhibitor	Sanofi (SNY)

Phase 2(7)

Drug	Company
ALN-4324	ALNYLAM PHARMACEUTICALS, INC. (ALNY)
asc30	CHINA PHARMA HOLDINGS, INC. (CPHI)
da-1241	MetaVia Inc. (MTVA)
GKT137831	Calliditas Therapeutics AB (CALT)
GSBR-1290	Structure Therapeutics Inc. (GPCR)
renal autologous cell therapy	PROKIDNEY CORP. (PROK)
vanoglipel	MetaVia Inc. (MTVA)

Phase 1(3)

Drug	Company
AGTX-2004 (DBPR211)	Agentix Corp. (AGTX)
LY3209590	ELI LILLY & Co (LLY)
RO7204239	Crinetics Pharmaceuticals, Inc. (CRNX)

Preclinical(1)

Drug	Company
dbsn device	Vyome Holdings, Inc (HIND)

Phase 1/Phase 2(1)

Drug	Company
ALN-KHK	ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Phase 4(4)

Drug	Company
Dapagliflozin 10mg Tab	ASTRAZENECA PLC (AZN)
insulin degludec	Sanofi (SNY)
insulin glargine	Sanofi (SNY)
Semaglutide	UNITED THERAPEUTICS Corp (UTHR)

BioSniper tracks 29 drugs in development for Type 2 Diabetes Mellitus across 20 companies.

There are 20 clinical trials targeting Type 2 Diabetes Mellitus tracked by BioSniper.

The estimated prevalence of Type 2 Diabetes Mellitus is approximately 10700.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.